文献速递免疫规划传染病防控与疫情报告

墨西哥新冠疫苗有效性:时间序列方法研究

The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
PubMed 文献 · Vaccine · 2024-11-30

结果显示疫苗有效性随时间呈凹函数,峰值分别为辉瑞92.6%、阿斯利康83.6%、科兴65.6%,出现在首剂接种后9至12周。结论认为三种疫苗均可预防有症状COVID-19,但保护水平不同。

要点

  • 辉瑞疫苗对有症状COVID-19的峰值有效性为92.6%。
  • 阿斯利康疫苗峰值有效性为83.6%,科兴为65.6%。
  • 两剂方案下疫苗有效性在首剂后9至16周达峰。

核心结论

  • 三种疫苗均对有症状COVID-19有保护作用,但保护水平不同。
  • 两剂方案下疫苗有效性在首剂接种后9至16周达到峰值。
  • 较早接种第二剂以提高效率与较晚接种以延长保护期之间似乎存在权衡。

研究设计与样本

  • 采用两步时间序列估计程序,并构建合成对照组。
  • 数据覆盖2020年3月第一周至2021年10月第一周。

主要发现

  • 疫苗有效性随时间呈凹函数。
  • 峰值有效性:辉瑞92.6%,阿斯利康83.6%,科兴65.6%。
  • 峰值出现在首剂接种后9至12周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effectiveness of several vaccine brands-Pfizer, Astra, and Sinovac-against symptomatic COVID-19 without information on vaccination at the individual level. METHODS: We use data of mass vaccination programs-specifically, for sexagenarians and quinquagenarians-in three large municipalities of Mexico (Monterrey, Guadalupe, and San Nicolás) to conduct a two-step time series estimation procedure involving a synthetic control group. The data covers the period between the first week of March 2020 and the first week of October 2021. RESULTS: Vaccine effectiveness is a concave function of time. At the peak, Pfizer reaches 92.6 % effectiveness, Astra 83.6 % and Sinovac 65.6 %. This occurs 9 to 12 weeks after the first shot. CONCLUSION: The results indicate that the three vaccines protect against symptomatic COVID-19. Nevertheless, they offer different levels of protection. The results also suggest that VE-under a two-shot scheme-reaches its peak 9 to 16 weeks after the first shot. Moreover, there seems to be a trade-off between achieving higher efficiency by administering the 2nd shot earlier or extending the protection period by administering it later.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Flores D, Luna EM. The effectiveness of vaccines against COVID-19 in Mexico: A time series approach. Vaccine. 2024. PMID: 39615344. doi:10.1016/j.vaccine.2024.126565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。